Clinical Trial Detail

NCT ID NCT03166254
Title Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.